Breaking News, Financial News

Financial Report: Elan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan 3Q Revenues: $270.1 million (+53%)  3Q Loss: $83.5 million  (loss of $87.4 million in 3Q07)  YTD Revenues: $730.4 million (+35%) YTD Loss: $240.5 million (loss of $321.5 million in YTD07) Comments: Biopharmaceuticals business grew by 85% driven by a strong performance from Tysabri, with Elan’s recorded sales up 159% to $164.5 million. Total in-market sales of Tysabri were $237.0 million in the quarter (+154%). Azactam sales were $24.2 million (+17%). Maxipime sales were $5...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters